Donald Trump’s order to lower prices may benefit generics, says Cipla CEO

Cipla anticipates that Donald Trump's order to lower US drug prices could favor generic drug companies like itself. The company reported a strong Q4 performance with a 30% increase in net profit. Cipla is optimistic about growth in India, particularly in the weight-loss drug market, and is exploring both organic and inorganic expansion opportunities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jPevCId
via IFTTT